Gregory E. Jones

871 total citations
15 papers, 622 citations indexed

About

Gregory E. Jones is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Gregory E. Jones has authored 15 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Gregory E. Jones's work include Monoclonal and Polyclonal Antibodies Research (7 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer therapeutics and mechanisms (5 papers). Gregory E. Jones is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer therapeutics and mechanisms (5 papers). Gregory E. Jones collaborates with scholars based in United States, Australia and France. Gregory E. Jones's co-authors include Yelena Kovtun, Charlene A. Audette, Ravi Chari, Victor S. Goldmacher, Wayne C. Widdison, Sharon Wilhelm, Rajeeva Singh, Jan Pinkas, Olga Ab and John M. Lambert and has published in prestigious journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Gregory E. Jones

14 papers receiving 607 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory E. Jones United States	8	463	350	188	106	64	15	622
Olga Ab United States	11	577 1.2×	398 1.1×	190 1.0×	99 0.9×	73 1.1×	23	776
Alan Wilhelm United States	9	273 0.6×	154 0.4×	128 0.7×	104 1.0×	47 0.7×	22	388
Katharine C. Lai United States	8	426 0.9×	342 1.0×	175 0.9×	42 0.4×	65 1.0×	17	590
Latha Sridharan United States	10	367 0.8×	230 0.7×	222 1.2×	77 0.7×	64 1.0×	11	656
Patrick H. van Berkel United Kingdom	9	393 0.8×	181 0.5×	112 0.6×	26 0.2×	96 1.5×	35	496
Kim K. Emmerton United States	11	414 0.9×	334 1.0×	211 1.1×	13 0.1×	57 0.9×	19	595
Heather Kostner United States	7	413 0.9×	208 0.6×	263 1.4×	107 1.0×	102 1.6×	12	624
Sreeni Yalamanchili United States	8	440 1.0×	80 0.2×	266 1.4×	64 0.6×	65 1.0×	17	634
Bart E.C.G. de Goeij Netherlands	8	408 0.9×	468 1.3×	322 1.7×	70 0.7×	189 3.0×	10	788
SJ Knox United States	12	142 0.3×	387 1.1×	134 0.7×	40 0.4×	111 1.7×	21	586

Countries citing papers authored by Gregory E. Jones

Since Specialization

Citations

This map shows the geographic impact of Gregory E. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory E. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory E. Jones more than expected).

Fields of papers citing papers by Gregory E. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory E. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory E. Jones. The network helps show where Gregory E. Jones may publish in the future.

Co-authorship network of co-authors of Gregory E. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory E. Jones. A scholar is included among the top collaborators of Gregory E. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory E. Jones. Gregory E. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Kovtun, Yelena, Gregory E. Jones, Sharlene Adams, et al.. (2018). A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Advances. 2(8). 848–858. 129 indexed citations

Kovtun, Yelena, Paul Noordhuis, Kathleen R. Whiteman, et al.. (2018). IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Molecular Cancer Therapeutics. 17(6). 1271–1279. 54 indexed citations

Kovtun, Yelena, Gregory E. Jones, Charlene A. Audette, et al.. (2016). A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells. Blood. 128(22). 768–768. 5 indexed citations

Hong, Erica, Hans K. Erickson, Robert J. Lutz, et al.. (2015). Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation. Molecular Pharmaceutics. 12(6). 1703–1716. 38 indexed citations

Cashin, Paul, et al.. (2015). Usefulness of early post‐operative liver function test monitoring after laparoscopic common bile duct exploration. ANZ Journal of Surgery. 87(11). 925–929. 7 indexed citations

Widdison, Wayne C., Sharon Wilhelm, Gregory E. Jones, et al.. (2015). Metabolites of Antibody–Maytansinoid Conjugates: Characteristics andin VitroPotencies. Molecular Pharmaceutics. 12(6). 1762–1773. 22 indexed citations

Singh, Rajeeva, Nathan Fishkin, Yelena Kovtun, et al.. (2013). Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).. Molecular Cancer Therapeutics. 12(11_Supplement). C164–C164.

Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2013). Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).. Molecular Cancer Therapeutics. 12(11_Supplement). C160–C160. 1 indexed citations

Zhao, Robert Y., Sharon Wilhelm, Charlene A. Audette, et al.. (2011). Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates. Journal of Medicinal Chemistry. 54(10). 3606–3623. 150 indexed citations

10.

Kovtun, Yelena, Charlene A. Audette, Michele Mayo, et al.. (2010). Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance. Cancer Research. 70(6). 2528–2537. 194 indexed citations

11.

Kovtun, Yelena, Gregory E. Jones, Charlene A. Audette, et al.. (2010). 235 Negatively-charged sulfonate group in linker improves potency of antibody–maytansinoid conjugates against multidrug-resistant cancer cells. European Journal of Cancer Supplements. 8(7). 76–77. 1 indexed citations

12.

Widdison, Wayne C., Sharon Wilhelm, Yelena Kovtun, et al.. (2010). Abstract 2668: Detoxification of metabolites from antibody-maytansinoid conjugates by human liver microsomes. Cancer Research. 70(8_Supplement). 2668–2668. 1 indexed citations

13.

Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2009). Abstract B126: Potent antigen-specific anti-tumor activity observed with antibody-drug conjugates (ADCs) made using a new class of DNA-crosslinking agents. Molecular Cancer Therapeutics. 8(12_Supplement). B126–B126. 5 indexed citations

14.

Lehmann, Jöerg, Robin L. Stern, David M. Rocke, et al.. (2006). Dosimetry for Quantitative Analysis of the Effects of Low-Dose Ionizing Radiation in Radiation Therapy Patients. Radiation Research. 165(2). 240–247. 13 indexed citations

15.

Lehmann, Jöerg, et al.. (2004). Dosimetry for quantitative analysis of low dose ionizing radiation effects on humans in radiation therapy patients. Radiation Research. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact